While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...
Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...
Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...
The Oncology Nursing Society (ONS) is developing a skin of color toxicity photo repository with funding from a grant from La Roche-Posay to support oncology nurses in recognizing ...
Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial. Neoadjuvant and adjuvant enfortumab vedotin ...
While every patient with cancer will have psychosocial needs, understanding when to assess those needs and what professionals to connect a patient with are key to supporting patie ...
Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s ...
The FDA has approved encorafenib plus cetuximab and fluorouracil-based chemotherapy in patients with BRAF V600E-positive metastatic colorectal cancer. The FDA has approved encorafenib (Braftovi) ...
Treatment with systemic intravenous olvimulogene nanivacirepvec (Olvi-Vec) led to promising preliminary results in patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC ...
AI in oncology nursing remains in its early stages, but it’s already reshaping health care. This moment was evident at the 2025 American Society of Hematology Annual Meeting and Exposition, which ...
The FDA has approved acalabrutinib plus venetoclax in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The FDA has approved the use of acalabrutinib (Calquence) tablets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results